Amgen Inc. (NASDAQ:AMGN) Enjoys Robust Institutional Support with 81% Ownership
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 12 2025
0mins
Should l Buy AMGN?
Source: Yahoo Finance
Institutional Influence: Institutions hold approximately 81% of Amgen's shares, indicating significant influence over the company's share price and decision-making, with the top 18 shareholders controlling 50% of the ownership.
Insider Ownership and Public Stake: Insiders own less than 1% of Amgen, while the general public holds a 19% stake, suggesting that while institutional investors dominate, retail investors can still impact company policies.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AMGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AMGN
Wall Street analysts forecast AMGN stock price to fall
24 Analyst Rating
14 Buy
9 Hold
1 Sell
Moderate Buy
Current: 375.430
Low
280.00
Averages
363.10
High
425.00
Current: 375.430
Low
280.00
Averages
363.10
High
425.00
About AMGN
Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investment Opportunities in Biotech Stocks
- AbbVie Financial Performance: In 2025, AbbVie achieved full-year revenues of $61.2 billion, an 8.6% year-over-year increase, with the ex-Humira growth platform accelerating to 14.5% in Q4, indicating strong growth potential in immunology and oncology.
- Technical Support Analysis: AbbVie shares are currently trading around $230, comfortably above the 50-day moving average and near the 200-day moving average, which serves as a critical support level; maintaining above this level could sustain the long-term uptrend, while a breach may signal a technical pullback risk.
- Amgen Revenue Growth: In 2025, Amgen reported revenues of $36.8 billion, a 10% year-over-year increase, with 18 products achieving record sales, showcasing its competitive strength in cardiovascular, bone health, and oncology markets.
- Market Trend Observation: Amgen's stock is currently pulling back towards the 50-day moving average; if it finds support around $352, it could present a lower-risk entry point for investors, whereas a drop below the 200-day moving average may indicate a more significant trend reset.
See More
Intensifying Competition in Weight Loss Drug Market
- Novo Nordisk's Market Leadership: Novo Nordisk's GLP-1 drug Wegovy has become a best-seller in the weight loss sector, and with the recent launch of its oral version, it is expected to further solidify its market share and drive growth in the coming years.
- New Drug Development Progress: Novo Nordisk's CagriSema has outperformed Wegovy in clinical studies and is under consideration for approval, while amycretin and UBT251 are also undergoing trials, which could significantly expand its portfolio of weight loss medications if successful.
- Amgen's Potential Advantage: Amgen's MariTide is currently in phase 3 studies and could gain approval within the next three years; its monthly dosing regimen is more appealing compared to Novo Nordisk's weekly schedule, potentially allowing it to carve out a niche in the market.
- Investment Risk Assessment: While Novo Nordisk has a stronger portfolio of weight loss drugs, it has lost market share to competitor Eli Lilly, whereas Amgen's diversified product lineup offers greater resilience, making it a safer choice for investors.
See More
Novo Nordisk vs. Amgen: Weight Loss Drug Competition
- Market Leadership: Novo Nordisk leads the weight loss market with its GLP-1 drug Wegovy, and the recent launch of its oral version further solidifies its market share, with expectations to expand its portfolio of weight loss medicines in the coming years, driving company growth.
- R&D Progress: Novo Nordisk's CagriSema outperformed Wegovy in clinical studies and is under consideration for approval, while candidates like amycretin and UBT251 are also in active development, showcasing the company's strong R&D capabilities in the weight loss sector.
- Amgen's Potential: Although Amgen has yet to launch a weight loss drug, its candidate MariTide is in phase 3 studies and could gain approval within the next three years, with its monthly dosing regimen potentially providing a competitive edge.
- Investment Risk Assessment: Novo Nordisk's growth is heavily reliant on the performance of its weight loss drugs, while Amgen offers a more diversified product portfolio, suggesting that even if its weight loss market performance is uncertain, its overall business resilience may provide investors with lower risk.
See More
Intensifying Competition in Weight Loss Drug Market
- Novo Nordisk's Market Leadership: Novo Nordisk's GLP-1 drug Wegovy has become a best-seller in the weight loss sector, and its newly launched oral version is expected to further expand market share, driving company growth in the coming years.
- New Drug Development Progress: Novo Nordisk's CagriSema has outperformed Wegovy in clinical studies and is under consideration for approval, while amycretin in phase 3 studies and UBT251 showing strong efficacy in mid-stage trials in China further enrich its weight loss drug portfolio.
- Amgen's Potential Advantage: Although Amgen has yet to gain approval for a weight loss drug, its candidate MariTide is in phase 3 studies and could receive approval within three years, with its monthly dosing regimen potentially providing a competitive edge.
- Investment Risk Assessment: While Novo Nordisk has a stronger portfolio of weight loss products, it has lost market share to competitor Eli Lilly, making Amgen's diversified product lineup a potentially safer investment choice with lower entry risks in the weight loss market.
See More
FDA Vaccine and Biotech Chief Resigns Amid Industry Criticism
- Regulatory Uncertainty Intensifies: Vinay Prasad, director of the FDA's Center for Biologics Evaluation and Research, will resign at the end of April amid widespread criticism from the biotech and pharmaceutical industries for denying or hindering at least eight drug approval applications, potentially stifling new drug development.
- Strong Industry Backlash: Prasad's resignation highlights a crisis of trust within the FDA's drug approval process, particularly as companies express confusion and dissatisfaction with the agency's guidance, which may impact future drug research and development.
- Pressure for Internal Reform: Under Health and Human Services Secretary Robert F. Kennedy Jr., the FDA has undergone staff cuts and restructuring, further exacerbating external doubts about its drug and vaccine approval processes, which could jeopardize patient safety.
- Successor Yet to Be Named: FDA Commissioner Marty Makary stated that a successor will be appointed before Prasad's departure, and while Prasad achieved certain accomplishments during his tenure, his resignation may affect the FDA's future decisions and industry confidence.
See More
Amgen to Present at Global Healthcare Conference
- Conference Participation: Amgen will present at the Leerink Partners 2026 Global Healthcare Conference on March 11, 2026, starting at 9:20 a.m. ET, showcasing its latest advancements in the healthcare sector and enhancing its visibility among investors and the public.
- Executive Attendance: CFO Peter Griffith and Senior VP of Rare Disease Jasper van Grunsven will participate in a fireside chat, sharing insights on the company's innovations and strategies in rare disease treatment, which is expected to bolster investor confidence.
- Webcast Availability: The conference will be broadcast live over the internet, accessible to media, investors, and the general public, with links provided on Amgen's Investor Relations Events Calendar, ensuring broad audience engagement and transparency.
- Long-term Replay: The webcast will be archived and available for replay for at least 90 days post-event, providing convenience for those unable to attend live and demonstrating Amgen's commitment to information dissemination, further solidifying its leadership in the biotechnology industry.
See More
Investment Opportunities in Biotech Stocks
- AbbVie Financial Performance: In 2025, AbbVie achieved full-year revenues of $61.2 billion, an 8.6% year-over-year increase, with the ex-Humira growth platform accelerating to 14.5% in Q4, indicating strong growth potential in immunology and oncology.
- Technical Support Analysis: AbbVie shares are currently trading around $230, comfortably above the 50-day moving average and near the 200-day moving average, which serves as a critical support level; maintaining above this level could sustain the long-term uptrend, while a breach may signal a technical pullback risk.
- Amgen Revenue Growth: In 2025, Amgen reported revenues of $36.8 billion, a 10% year-over-year increase, with 18 products achieving record sales, showcasing its competitive strength in cardiovascular, bone health, and oncology markets.
- Market Trend Observation: Amgen's stock is currently pulling back towards the 50-day moving average; if it finds support around $352, it could present a lower-risk entry point for investors, whereas a drop below the 200-day moving average may indicate a more significant trend reset.
See More
Intensifying Competition in Weight Loss Drug Market
- Novo Nordisk's Market Leadership: Novo Nordisk's GLP-1 drug Wegovy has become a best-seller in the weight loss sector, and with the recent launch of its oral version, it is expected to further solidify its market share and drive growth in the coming years.
- New Drug Development Progress: Novo Nordisk's CagriSema has outperformed Wegovy in clinical studies and is under consideration for approval, while amycretin and UBT251 are also undergoing trials, which could significantly expand its portfolio of weight loss medications if successful.
- Amgen's Potential Advantage: Amgen's MariTide is currently in phase 3 studies and could gain approval within the next three years; its monthly dosing regimen is more appealing compared to Novo Nordisk's weekly schedule, potentially allowing it to carve out a niche in the market.
- Investment Risk Assessment: While Novo Nordisk has a stronger portfolio of weight loss drugs, it has lost market share to competitor Eli Lilly, whereas Amgen's diversified product lineup offers greater resilience, making it a safer choice for investors.
See More
Novo Nordisk vs. Amgen: Weight Loss Drug Competition
- Market Leadership: Novo Nordisk leads the weight loss market with its GLP-1 drug Wegovy, and the recent launch of its oral version further solidifies its market share, with expectations to expand its portfolio of weight loss medicines in the coming years, driving company growth.
- R&D Progress: Novo Nordisk's CagriSema outperformed Wegovy in clinical studies and is under consideration for approval, while candidates like amycretin and UBT251 are also in active development, showcasing the company's strong R&D capabilities in the weight loss sector.
- Amgen's Potential: Although Amgen has yet to launch a weight loss drug, its candidate MariTide is in phase 3 studies and could gain approval within the next three years, with its monthly dosing regimen potentially providing a competitive edge.
- Investment Risk Assessment: Novo Nordisk's growth is heavily reliant on the performance of its weight loss drugs, while Amgen offers a more diversified product portfolio, suggesting that even if its weight loss market performance is uncertain, its overall business resilience may provide investors with lower risk.
See More
Intensifying Competition in Weight Loss Drug Market
- Novo Nordisk's Market Leadership: Novo Nordisk's GLP-1 drug Wegovy has become a best-seller in the weight loss sector, and its newly launched oral version is expected to further expand market share, driving company growth in the coming years.
- New Drug Development Progress: Novo Nordisk's CagriSema has outperformed Wegovy in clinical studies and is under consideration for approval, while amycretin in phase 3 studies and UBT251 showing strong efficacy in mid-stage trials in China further enrich its weight loss drug portfolio.
- Amgen's Potential Advantage: Although Amgen has yet to gain approval for a weight loss drug, its candidate MariTide is in phase 3 studies and could receive approval within three years, with its monthly dosing regimen potentially providing a competitive edge.
- Investment Risk Assessment: While Novo Nordisk has a stronger portfolio of weight loss products, it has lost market share to competitor Eli Lilly, making Amgen's diversified product lineup a potentially safer investment choice with lower entry risks in the weight loss market.
See More
FDA Vaccine and Biotech Chief Resigns Amid Industry Criticism
- Regulatory Uncertainty Intensifies: Vinay Prasad, director of the FDA's Center for Biologics Evaluation and Research, will resign at the end of April amid widespread criticism from the biotech and pharmaceutical industries for denying or hindering at least eight drug approval applications, potentially stifling new drug development.
- Strong Industry Backlash: Prasad's resignation highlights a crisis of trust within the FDA's drug approval process, particularly as companies express confusion and dissatisfaction with the agency's guidance, which may impact future drug research and development.
- Pressure for Internal Reform: Under Health and Human Services Secretary Robert F. Kennedy Jr., the FDA has undergone staff cuts and restructuring, further exacerbating external doubts about its drug and vaccine approval processes, which could jeopardize patient safety.
- Successor Yet to Be Named: FDA Commissioner Marty Makary stated that a successor will be appointed before Prasad's departure, and while Prasad achieved certain accomplishments during his tenure, his resignation may affect the FDA's future decisions and industry confidence.
See More
Amgen to Present at Global Healthcare Conference
- Conference Participation: Amgen will present at the Leerink Partners 2026 Global Healthcare Conference on March 11, 2026, starting at 9:20 a.m. ET, showcasing its latest advancements in the healthcare sector and enhancing its visibility among investors and the public.
- Executive Attendance: CFO Peter Griffith and Senior VP of Rare Disease Jasper van Grunsven will participate in a fireside chat, sharing insights on the company's innovations and strategies in rare disease treatment, which is expected to bolster investor confidence.
- Webcast Availability: The conference will be broadcast live over the internet, accessible to media, investors, and the general public, with links provided on Amgen's Investor Relations Events Calendar, ensuring broad audience engagement and transparency.
- Long-term Replay: The webcast will be archived and available for replay for at least 90 days post-event, providing convenience for those unable to attend live and demonstrating Amgen's commitment to information dissemination, further solidifying its leadership in the biotechnology industry.
See More
